The Novavax coronavirus vaccine proved 96.4 percent effective against the original variant of coronavirus and 86.3 percent effective against its British strain, Report informs, referring to RIA Novosti.
The third phase of the NVX CoV2373 vaccine trial took place in the UK. The study covered more than 15,000 participants aged 18-84, 27 percent of them were over 65.
The company also said that when it comes to severe form of COVID, the vaccine has demonstrated 100 percent effectiveness.